Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Rhea-AI Summary

Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in ENT and allergy treatments, has announced the cancellation of its Q4 and full-year 2024 earnings conference call originally scheduled for March 20, 2025. The cancellation follows the company's earlier announcement of a definitive agreement to be acquired by Paratek Pharmaceuticals.

The acquisition deal is subject to shareholder approval and other customary closing conditions. Despite the earnings call cancellation, Optinose confirms it will still report its financial results for both the three-month and twelve-month periods ended December 31, 2024, in a timely manner.

Positive

• Definitive agreement reached for acquisition by Paratek Pharmaceuticals

Negative

• None.

News Market Reaction – OPTN

+52.50%

+52.50% Session move

In the trading session that priced this news, OPTN gained 52.50%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time.

The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions.

The Company now expects to report results for the three- and twelve-month periods ended December 31, 2024, in a timely manner.

About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531

FAQ

Why did Optinose (OPTN) cancel its Q4 2024 earnings call?

Optinose cancelled the call due to the announcement of its pending acquisition by Paratek Pharmaceuticals.

Will Optinose (OPTN) still release its Q4 and full-year 2024 financial results?

Yes, Optinose confirmed it will report results for both Q4 and full-year 2024 in a timely manner.

What are the conditions for Paratek's acquisition of Optinose (OPTN)?

The acquisition requires shareholder approval and other customary closing conditions.

When was Optinose's (OPTN) Q4 2024 earnings call originally scheduled?

The earnings call was originally scheduled for March 20, 2025, at 8:00 a.m. Eastern Time.